| Literature DB >> 10718025 |
P J Neumann, E A Sandberg, C M Bell, P W Stone, R H Chapman.
Abstract
The argument that prescription drugs are cost-effective has been made both by the pharmaceutical industry to support rising drug prices and expenditures, and by advocates of expanded drug coverage for elderly and low-income persons. A new database of 228 published cost-utility analyses sheds light on the issue. According to published data, some drugs do save money or are cost-effective, but the issue depends critically on the context in which the drug is used and the intervention with which it is compared. Cost-utility analyses funded by the drug industry tend to report more favorable results than do those funded by nonindustry sources. Cost-effectiveness analysis can help policymakers to determine whether drugs and other interventions offer value for money.Entities:
Mesh:
Year: 2000 PMID: 10718025 DOI: 10.1377/hlthaff.19.2.92
Source DB: PubMed Journal: Health Aff (Millwood) ISSN: 0278-2715 Impact factor: 6.301